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Abstract 
Background 
GTP cyclohydrolase I (GCH1) mutations are the commonest cause of Dopa-
responsive dystonia (DRD). Clinical phenotypes can be broad, even within a single 
family.  
Methods 
We present clinical, genetic and functional imaging data on a British kindred in which 
affected subjects display phenotypes ranging from DRD to Parkinson’s disease (PD). 
Twelve family members were studied. Clinical examination, dopamine transporter 
(DAT) imaging, and molecular genetic analysis of GCH1 and the commonest known 
familial PD-related genes were performed. 
Results  
We have identified a novel missense variant, c.5A>G, p.(Glu2Gly), within the GCH1 
gene in affected family members displaying a range of phenotypes. 
Two affected subjects carrying this variant had abnormal DAT imaging. These two 
with abnormal DAT imaging had a PD phenotype, while the remaining three subjects 
with the novel GCH1 variant had normal DAT imaging and a DRD phenotype. 
Conclusions 
We propose that this GCH1 variant is pathogenic in this family and these findings 
suggest that similar mechanisms involving abnormal GTP cyclohydolase I may 
underlie both PD and DRD. GCH1 genetic testing should be considered in patients 
with PD and a family history of DRD. 
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Introduction 
Dopa-responsive dystonia (DRD) is an autosomal dominant dystonia, now classified 
as DYT5, with an estimated incidence of between 0.5 and 1 per million [1]. DRD 
typically manifests as lower limb dystonia in childhood, although the spectrum of 
symptoms can be broad, even within the same family. Patients typically have an 
excellent and sustained response to low dose levodopa. Women are more commonly 
affected with a lower penetrance of mutations in men [2, 3]. 
Mutations in the GTP cyclohydrolase I gene (GCH1) are the most common cause of 
DRD. GCH1 is located on chromosome 14 (14q22.1-q22.2) and encodes the 32-kDa  
guanosine 5'-triphosphate cyclohydrolase 1 (GTPCH1) protein. GCH1 contains six 
exons, and more than 200 different mutations have been identified [1, 2]. 
Single positron emission computerised tomography (SPECT) Dopamine Transporter 
(DAT) imaging is a demonstration of in vivo striatal dopamine activity. The DAT 
ligands for SPECT, including [123I]FP-CIT (DaTSCAN) have all shown significantly 
reduced striatal uptake in PD [4], whilst uptake has usually been normal in DRD [5]. 
We have studied a family with an inherited movement disorder, with phenotypes 
ranging from DRD to slowly progressive PD. We report results from clinical, genetic 
and imaging studies of this kindred.  
 
 
Methods 
Twelve members of the kindred were studied. A diagnosis of PD was made according 
to United Kingdom Parkinson’s Disease Society (UKPDS) Brain Bank clinical 
diagnostic criteria. The Hoehn and Yahr PD rating scale and a Folstein MMSE (Mini 
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Mental State Examination) were performed on each subject. Olfactory function was 
assessed by use of the University of Pennsylvania Smell Identification Test (UPSIT-
40) (Sensonics, Haddon Heights, NJ) and data compared to normative values. Seven 
subjects (II:1-II:5, III:1 and III:11) underwent dopamine transporter SPECT scanning 
(DaTSCAN, Amersham Health) and images reviewed by ER, who was blinded to 
demographic and clinical data.  
Molecular genetic screening of the six affected family members was performed by 
polymerase chain reaction (PCR) and sequencing of the entire coding sequence, and 
intron-exon boundaries, of the genes SNCA, Parkin, DJ-1, PINK1, LRRK2 and GCHI, 
using primers and PCR conditions available on request. Multiple ligation-dependent 
probe amplification (MLPA) was used to detect the presence or absence of copy 
number variation, using MLPA kits P051 and P052 (MRC Holland), details available 
on request. Subsequently, six unaffected family members (II:2 and III:4,5,7,9,13) and 
150 UK control DNA samples from the PD GEN DNA databank were screened for 
the novel GCH1 variant. 
All subjects gave informed written consent to take part in the study. The study had 
appropriate ethical approval from South Birmingham LREC and Sandwell and West 
Birmingham LREC.  
 
Results 
Twelve individuals in the pedigree (figure 1, those annoted with an age) were 
examined in detail. We noted features consistent with slowly progressive PD in 
individuals II:1 and II:4 (supplementary video), with additonal levodopa-induced 
dyskinesias and dementia in subject II:1. Disease onset was at 58 and 50 years in II:1 
and II:4 respectively. Subject II:3 had an isolated rest tremor (asymmetrical, right 
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upper limb), with an older age of onset of 75 years, had not progressed over six years 
and did not meet diagnostic criteria for PD. Subjects II:5, III:1 and III:11 had features 
consistent with DRD, with median age of disease onset 17 years and median disease 
duration of 22 years. The remaining members of the family were unaffected. All the 
studied subjects are Caucasian and clinical details of affected individuals are 
summarised in Table 1 (more clinical details in supplementary data). 
The findings from DaTSCAN images on six affected subjects (II:1, II:3-II:5, III:1 and 
III:11) and one unaffected subject (II:2) are summarised in table 1 (supplementary 
data). Subjects II:3 and II:4 had a second DaTSCAN performed 18 months after the 
first scan due to atypical disease progression (ie only very slowly progressing which 
would be unexpected in idiopathic PD). 
No novel or previously documented mutations were identified in the coding 
sequences of SNCA, Parkin, PINK1, DJ-1 and LRRK2. However, a novel 
heterozygous substitution was identified in the first exon of GCH1 affecting the fifth 
nucleotide of the open reading frame (c.5A>G) (supplementary data). This change is 
predicted to replace a glutamic acid residue with glycine (p.(Glu2Gly)). This mutation 
(GenBank accession NM_000161.2, NP_000152.1.) is not listed as a known mutation 
or polymorphism in standard databases (dbSNP138 
(http://www.ncbi.nlm.nih.gov/SNP/); 1000 genomes (release October 2013, 
http://browser.1000genomes.org.); Exome Variant Server (HLBI-EPS6500, 
http://evs.gs.washington.edu/EVS/ database accessed Sept, 2014). The novel GCH1 
variant was identified in five of the affected members of the family, but not in subject 
II:3 or unaffected subjects II:2 and III:4,5,7,9,13, nor in 300 UK control 
chromosomes. MLPA did not reveal any copy number variation in SNCA, Parkin, 
PINK1, DJ-1 and LRRK2 or GCH1. 
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Discussion 
We have identified a novel heterozygous missense variant within GCH1 (c.5A>G) in 
five family members affected by PD or DRD. Several arguments support the 
contention that this variant is pathogenic. The variant cosegregates with disease state 
in the family; it is absent from 300 UK control chromosomes tested here, and from all 
the large public databases; furthermore, it is almost completely conserved among 
species (Supp Fig.  2), and it is predicted to replace one of the larger hydrophilic 
amino acids with a small hydrophobic glycine within the N-terminal region of the 
protein. It is well known that in-silico prediction tools possess limited accuracy [6]. 
This mutation is predicted as pathogenic by SIFT and SNP&GO, but not by 
PolyPhen-2 and Mutation Taster. The clinical symptoms and signs observed in 
subjects II:1 and II:4 met diagnostic criteria for PD. In both cases the disease was 
more slowly progressive than is usual in idiopathic PD. Subject II:3 had an isolated 
rest tremor and subjects II:5, III:1 and III:11 were diagnosed with DRD. The 
symptoms in subjects III:1 and III:11 started at a young age and in the case of subject 
III:11 were more severe than those seen in subject II:5, illustrating the extreme 
phenotypic heterogeneity in this kindred and possibly reflecting the increased 
penetrance of GCH1 mutations in females. 
DaTSCAN data supported the clinical diagnoses in most cases. The clinical 
phenotypes of DRD and PD and correspondingly normal and abnormal scans were 
found in subjects carrying the same GCH1 mutation. DAT imaging is typically 
normal in DRD. Indeed DAT imaging has been proposed as a diagnostic tool to help 
differentiate between DRD and early onset PD [5]. There have been case reports of 
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individuals with adult onset dystonia-parkinsonism [7] or PD without any dystonia [8] 
carrying a GCH1 mutation and an abnormal DaTSCAN. 
Recently, Mencacci and colleagues reported 4 unrelated individuals with adult onset 
parkinsonism, presumed pathogenic GCH1 mutations and abnormal DaTSCANs [9].  
These cases, and the two in our family (subjects III:1 and III:4), raise the question as 
to whether PD, in patients with presumed pathogenic GCH1 mutations, is in fact a 
rare phenotype of DRD. Certainly the phenotype of DRD is suggested to be broad, as 
illustrated by a recently reported family with classical DRD, adult onset PD and an 
MSA-like phenotype associated with a GCH1 two exon deletion [3]. As recently 
speculated by Mencacci and colleagues [9], chronic dopamine deficiency resulting 
from GCH1 deficiency could directly predispose to nigral cell death (rather than 
classical lewy body associated neurodegeneration as typically seen in PD). Although 
earlier studies screening for a GCH1 mutations in PD cohorts did not identify a 
significant role for genetic variation in GCH1, recent studies have implicated GCH1 
as a risk locus for PD [9, 10]. 
 
An alternative, but less plausible, explanation in our family is the coincident 
occurrence of two separate movement disorders: a GCH1 mutation causing DRD in 
some individuals an additional mutation (ie an unidentified mutation in an as yet 
unidentified PD gene) causing PD coincidentally in others. In those with a GCH1 
mutation and PD but no dystonia the lack of DRD phenotype could then be explained 
by incomplete penetrance of the GCH1 mutation. 
 
Olfactory dysfunction is found in 70-100% of PD patients. As DRD is a result of 
dopamine deficiency without neuronal cell death, we would predict that UPSIT-40 
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data in DRD should be normal. In our study, the mean UPSIT-40 score for affected 
subjects with the GCH1 mutation was 29.4, compared to a previous study of olfaction 
in PD, in which the mean score in 18 subjects with idiopathic PD was 17.1, with a 
score of 27.6 in 27 age-matched controls [11]. The small sample sizes which result 
from separating our individuals with the GCH1 mutation limit any conclusions but the 
2 individuals with PD had a mean score of 24.5 versus the 3 with DRD who had a 
mean score 32.7. 
 
The DaTSCAN data for subject III:3, who had an isolated rest tremor, is difficult to 
explain. His first scan was abnormal, but the second scan performed 18 months later 
was normal. One explanation is that he suffered a vascular embolic event occurring 
around the time of the first scan. An alternative explanation is that there was a 
technical problem with one of the scans. There is also a category of subjects with 
parkinsonism who have normal DaTSCANs, so called SWEDDs (Scans Without 
Evidence of Dopaminergic Deficit), with 11-15% of subjects with PD being found to 
have normal nigrostriatal uptake of presynaptic ligands [12]. The novel GCH1 
mutation is not carried by subject III:3 and the most likely explanation for his 
symptoms is that he has isolated rest tremor due to an unrelated mechanism. 
 
In further studies we will screen for GCH1 variants in subjects with familial PD, and 
in subjects with parkinsonism who have normal DAT scans, as well as pursuing 
further studies into the functional effects of the novel variant described here. We 
anticipate that future post-mortem histological data on affected individuals, 
particularly those with the PD phenotype will shed more light on disease mechanisms 
in this interesting family. 
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Figure legends. 
 
Figure 1 Pedigree of study family. Numbers refer to the age (in years) at clinical 
evaluation and blood sampling of the twelve family members studied. 
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Table 1 Summary of the clinical, functional neuro-imaging and molecular genetic data 
on subjects from the study family. PD denotes Parkinson’s disease; DRD dopa responsive 
dystonia; N/A not done or not appropriate; MMSE mini mental state examination score; 
UPSIT University of Pennsylvania Smell Identification Test; DaTSCAN dopamine 
transporter imaging; Mod. moderate. Age and sex corrected percentile values for UPSIT 
scores are presented in brackets. 
 
Subject  
& 
gender 
Age 
at 
eval
Age at 
sympt. 
onset 
Clinical 
Diagnosis 
L-Dopa 
Response 
H&Y 
Stage 
MMSE 
UPSIT score 
(percentile) 
DaT 
SCAN 
GCH1 
mut.  
p.E2G 
II:1 M 82 58 PD Y 3 27 
21 (40th) 
Severe microsmia 
 
A Y 
II:2 M 80 N/A Unaffected N/A N/A 27 
31 (71st) 
Mild microsmia 
 
N N 
II:3 M 78 75 
Isolated rest 
tremor 
No Rx 1 30 
21 (23rd) 
Severe microsmia 
 
1 A 
2 N 
N 
II:4 M 68 50 PD Y 2 29 
28 (31st) 
Mod. microsmia 
 
1 A 
2 A 
Y 
II:5 M 66 44 DRD Y N/A 28 
26 (24th) 
Mod. microsmia 
N Y 
III:1 F 56 17 DRD Y N/A 30 
35 (38th) 
Normosomia 
N Y 
III:11 F 26 6 DRD Y N/A 29 
37 (40th) 
Normosmia 
N Y 
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I
II
III
1 2
Parkinson’s disease (PD)
Proband
1
82
Dopa-responsive Dystonia (DRD)
2
80
1
56
4
45
5
50
7
50
2
3
78
Isolated rest tremor
4
68
9
35
11
26
5
66
13
40
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• We have identified a novel missense variant, c.5A>G, p.(Glu2Gly), within the 
GCH1 gene in affected family members displaying a range of phenotypes 
including dopa responsive dystonia (DRD) and slowly progressive 
parkinsonism. 
• Those with parkinsonism had abnormal DaTscans, indicating nigrostriatal 
neurodegeneration. 
• These findings suggest that similar mechanisms involving abnormal GTP 
cyclohydolase I may underlie both Parkinson’s disease and Dopa responsive 
Dystonia. 
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Subject II:1  
The proband case II:1 is a right-handed male, he was aged 82 at the time of evaluation 
and had onset of symptoms aged 58. His initial symptom was a resting tremor of the 
right hand. A diagnosis of PD was made and he was started on Levodopa (Sinemet) 
with significant treatment benefit. His symptoms have progressed slowly since 
diagnosis and his anti-parkinsonian medication has been increased.  
At the time of evaluation he had had intermittent ‘off-period’ dystonia of the right leg 
for about 5 years and had also had treatment-induced dyskinesias of the right arm, as 
well as of the head and neck, for approximately 10 years. He did not have any 
significant problem with ‘off-time’ or fluctuations in his motor symptoms. His past 
medical history included hypertension as well as colon and skin cancer. He was 
retired and had worked as a chef for 26 years. He had never smoked and had lived 
most of his life in the town.  
Neurological examination, on treatment, revealed features typical of PD with mask-
like facies, asymmetrical rest tremor, bradykinesia and cog wheeling rigidity, all 
worse on the right side, as well as postural instability with retropulsion on the pull test 
and dyskinesias. His gait was slow with reduced arm-swing on the right side. His 
Hoehn and Yahr stage was 3, with a UPDRS III score of 31. The remainder of his 
neurological examination was normal. There was no evidence of significant cognitive 
deficit with a MMSE score of 27. His anti-parkinsonian medication at time of 
evaluation consisted of Levodopa (Sinemet) at a total daily dose of 650mg.  
CT scanning of his brain, aged 84, showed cerebral atrophy, commensurate with his 
age.  
The clinical diagnosis in this subject was a slowly progressive form of PD. 
 
Subject II:2  
He is a left-handed male, was aged 80 at the time of evaluation and was 
asymptomatic. His past medical history included hypertension and osteoarthritis. He 
was retired and had been a railway worker for 50 years. He was an ex-smoker with a 5 
year pack history and had lived most of his life in the town. Neurological examination 
revealed no features of PD. There was no evidence of significant cognitive deficit 
with a MMSE score of 27.  
 
Subject II:3  
He is a right-handed male, was aged 78 at the time of evaluation and had onset of 
symptoms aged 75. His initial symptoms were a resting tremor of the right hand and 
slow gait. A diagnosis of parkinsonism was made, although his symptoms had not 
worsened since their onset and at the time of evaluation he had not received any anti-
parkinsonian therapy. He was reported to have had two cerebrovascular accidents 
(CVAs); the first was at the age of 65 when he had transient balance problems and the 
second episode was at the age of 71, when he had developed left arm weakness and 
dysarthria. His past medical history included angina and atrial fibrillation. He was 
retired and had worked as a hairdresser for 50 years. He was an ex-smoker with a 20 
year pack history and had lived most of his life in the town.  
Neurological examination revealed some features of parkinsonism, with an 
asymmetrical rest tremor, bradykinesia and cog wheeling rigidity, all worse on the 
right side. His gait was slow but was within normal limits. His Hoehn and Yahr stage 
was 1, with a UPDRS III score of 9. The remainder of his neurological examination 
was normal. There was no evidence of cognitive deficit with a MMSE score of 30.  
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Neither a CT scan of his brain, aged 73, nor an MRI scan of his brain, aged 78, had 
revealed any evidence of a CVA.  
The clinical diagnosis in this subject was parkinsonism as he did not meet the UKPDS 
brain bank diagnostic criteria for definite PD. 
 
Subject II:4  
He is a right-handed male, was aged 68 at the time of evaluation and had onset of 
symptoms aged 50. His initial symptoms were a resting tremor of the left hand and 
slow gait. A diagnosis of PD was made and he was initially commenced on Levodopa 
(Sinemet) 150mg daily, with significant treatment benefit. His symptoms had 
progressed slowly since diagnosis and were well controlled on a small dose of anti-
parkinsonian medication. His past medical history included angina, hypertension and 
erectile dysfunction. He was retired and had worked as an exhibition designer for over 
30 years. He had never smoked and had lived most of his life in the town.  
Neurological examination, on treatment, revealed features suggestive of PD, namely 
an impassive face, asymmetrical rest tremor, bradykinesia and cog wheeling rigidity, 
all worse on the left side. His gait was slow and he had poor arm swing, again worse 
on the left side. He also had evidence of postural instability with retropulsion on the 
pull test. His Hoehn and Yahr stage was 2, with a UPDRS III score of 19. The 
remainder of neurological examination was normal. There was no evidence of 
significant cognitive deficit with a MMSE score of 28. His anti-parkinsonian 
medication at time of evaluation consisted of Levodopa (Sinemet) at a total daily dose 
of 150mg.  
He underwent an MRI scan of his brain, aged 69, which revealed some areas of non-
specific increased signal in the right lentiform nucleus and around the posterior horns 
of both lateral ventricles, consistent with long-standing hypertension.  
The clinical diagnosis in this subject was of a slowly progressive form of PD.  
 
Subject II:5  
He is a right-handed male, was aged 66 at the time of evaluation and had onset of 
symptoms aged 44. His initial symptoms were a shuffling gait, difficulty with gait 
initiation and tremor of both legs. He was initially diagnosed with PD and 
commenced on a dopamine agonist (Bromocriptine) with significant treatment 
benefit. His symptoms progressed slowly, although Levodopa was added to his 
therapy six years after diagnosis, at the age of 50, to give a total daily levodopa 
equivalent dose of 250mg.  
At the time of initial evaluation, his symptoms were well controlled on treatment. His 
past medical history included erectile dysfunction but was otherwise unremarkable. 
He was retired and had worked as retail store manger for 30 years. He had never 
smoked and had lived most of his life in the town. His neurological examination at 
this time, on treatment, appeared to be normal with no evidence of the features of PD. 
There was no evidence of significant cognitive deficit with a MMSE score of 28. His 
anti-parkinsonian medication at time of evaluation consisted of dopamine agonist 
(Bromocriptine) and Levodopa (Sinemet) to give a total daily levodopa equivalent 
dose of 250mg.  
This subject was subsequently re-evaluated by Dr David Nicholl, and given a trial 
period of one week off anti-parkinsonian therapy. During this period his symptoms 
worsened, he developed a feeling of akathisia and a resting tremor of both feet. He 
also developed some dystonic posturing of both feet, worse on the right, which tended 
to be worse at the end of the day. Neurological examination at this time revealed 
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dystonic posturing of the right foot and resting tremor of both feet. On restarting anti-
parkinsonian medication the symptoms improved.  
The clinical diagnosis in this subject was DRD.  
 
Subject III:11  
She is a right-handed female, was aged 26 at the time of evaluation and had onset of 
symptoms aged 6. Her initial symptoms were a clawing of the toes and in-turning of 
the ankle of the right foot. Her symptoms progressed slowly but she subsequently 
developed similar symptoms of the left foot. No specific neurological diagnosis was 
made. At the age of 24 she developed dystonic posturing of the right hand, especially 
when typing or writing. All of these symptoms were worse in the evening or when 
stressed. Her past medical history was unremarkable. She was a secretary, had never 
smoked and had lived most of her life in the town.  
Neurological examination at the time of evaluation, off treatment, revealed the 
presence of a dystonic tremor of the right hand with a tendency to claw and she 
developed dystonic writer’s cramp whilst writing. Both feet were dystonic and were 
inverted. There were no other abnormal neurological features in the upper or lower 
limbs and allowing for the dystonic posturing of her feet her gait appeared within 
normal limits. There was no evidence of significant cognitive deficit with a MMSE 
score of 29.  
She was also assessed by Dr David Nicholl and given a working diagnosis of DRD. 
MRI scanning of her brain revealed an apparent persistence of non-myelinated white 
fibres around the trigones, occipital and frontal horns. She was commenced on 
Levodopa (Sinemet), with significant treatment benefit, and the dose was titrated up 
to a total daily dose of 300mg.  
The clinical diagnosis in this subject was DRD.  
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